Stay updated on PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial
Sign up to get notified when there's something new on the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page.

Latest updates to the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page
- Check4 days agoChange DetectedA new revision label (Revision: v3.3.3) was added to the History. The HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed from the footer.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check33 days agoChange DetectedThe Record History now includes a new revision entry v3.3.2 and removes v3.2.0 from the list. This updates the visible revision history and reflects the latest changes to the trial record.SummaryDifference0.1%

- Check40 days agoChange DetectedThe government funding notice/banner at the top of the page has been removed, and the trial record content and navigation remain unchanged; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check54 days agoChange DetectedVersion history shows updates to Study Status and Recruitment Status, including changes to Contacts/Locations. These updates reflect changes in the trial's current activity and site information.SummaryDifference0.1%

- Check83 days agoChange DetectedAdded a prominent operating-status notice and a v3.2.0 version tag, replacing the prior v3.1.0 revision.SummaryDifference13%

- Check90 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.3%

Stay in the know with updates to PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page.